Overview

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (CLARITY-2)

Status:
Completed

Trial end date:
2020-05-21

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of adjunctive pimavanserin compared to placebo in subjects with major depressive disorder who have an inadequate response to antidepressant therapy

Phase:

Phase 3

Details

Lead Sponsor:

ACADIA Pharmaceuticals Inc.

Treatments:

Antidepressive Agents
Pimavanserin